FLGT trades 16.7% above Wall Street's consensus target of $15.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FLGT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Fulgent Genetics, Inc. (FLGT) has a Wall Street consensus price target of $15.00, based on estimates from 9 covering analysts. With the stock currently trading at $18.00, this represents a potential downside of -16.7%. The company has a market capitalization of $535M.
Analyst price targets range from a low of $15.00 to a high of $15.00, representing a 0% spread in expectations. The median target of $15.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FLGT trades at a trailing P/E of -9.1x. Analysts expect EPS to grow +21.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NTRANatera, Inc. | $33.1B | $231.41 | $259.88 | +12.3% | Buy | — | 27 |
EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
PACBPacific Biosciences of California, Inc. | $435M | $1.40 | $1.00 | -28.6% | Buy | — | 18 |
LHLabcorp Holdings Inc. | $21.1B | $255.82 | $311.33 | +21.7% | Buy | 14.2x | 35 |
DGXQuest Diagnostics Incorporated | $21.6B | $195.00 | $220.57 | +13.1% | Hold | 18.1x | 34 |
MYRGMYR Group Inc. | $7.2B | $461.10 | $412.67 | -10.5% | Hold | 40.3x | 21 |
CDNACareDx, Inc | $1.4B | $26.18 | $27.00 | +3.1% | Buy | 28.0x | 13 |
PGNYProgyny, Inc. | $2.0B | $26.08 | $30.33 | +16.3% | Buy | 20.4x | 20 |
CSTLCastle Biosciences, Inc. | $641M | $21.12 | $43.50 | +106.0% | Buy | — | 11 |
ILMNIllumina, Inc. | $24.6B | $161.93 | $151.40 | -6.5% | Buy | 31.0x | 50 |
Quick answers to the most common questions about buying FLGT stock.
FLGT's consensus price target is $15, -16.7% below the current price of $18. The 9 analysts tracking FLGT see downside risk at present valuations.
FLGT has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $15 implies -16.7% downside from current levels.
FLGT's current price is $18 with a consensus target of $15 (-16.7% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $15 for FLGT, while the most conservative target is $15. The consensus of $15 represents the median expectation. These targets typically reflect 12-month expectations.
FLGT is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FLGT stock forecast based on 9 Wall Street analysts shows a consensus price target of $15, with estimates ranging from $15 (bear case) to $15 (bull case). The median consensus rating is "Buy".
Analysts are cautious on FLGT, with 0 Sell ratings and a price target of $15 (-16.7% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FLGT analyst price targets range from $15 to $15, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.